STOCK TITAN

Pediatrix Medical Group (MD) Financials

MD NYSE
Trailing 12 months to September 30, 2026
Revenue $2.0B +1.9% YoY
Net Income $150.1M -7.5% YoY
EPS (Diluted) $1.84 -3.7% YoY
Operating Cash Flow $226.9M -21.8% YoY
Market Cap $2.4B as of Nov 18, 2026
Price / Sales 1.2x on $2.0B revenue, trailing 12 months to September 30, 2026
Price / Earnings 16.1x on $150.1M net income, trailing 12 months to September 30, 2026
Price / Book 2.8x on $849.6M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MD SEC filings page.

Pediatrix Medical Group, Inc. (MD) reported $2.0B in revenue over the twelve months to Sep 30, 2026, up 1.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MD FY2025

Pediatrix’s FY2025 recovery came with lower revenue, as profitability and cash generation rebounded while debt and receivables fell.

Operating cash flow reached $271M against net income of $165M, showing reported earnings converted into more cash than they represented. That conversion coincided with receivables falling 11.7% while revenue fell 4.9%, suggesting collections contributed to cash improvement despite weaker sales.

Operating margin returned to 10.9% from -3.4%, a sharp reversal after two loss-making years. Revenue fell 4.9% while SG&A rose 1.0%, so the recovery reflects improvement elsewhere in operating results rather than simply selling more.

Balance-sheet liquidity improved without additional long-term borrowing: the current ratio was 1.7x while debt-to-equity was 0.7x. Current assets rose 19.4% as long-term debt fell 4.5%, indicating the stronger short-term position was not built through higher leverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 44 / 100
Financial Health Score (5 of 6 dimensions) 44/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Pediatrix Medical Group, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
43

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Pediatrix Medical Group, Inc. scores 43/100 on it among other operating companies.

Growth
23

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Pediatrix Medical Group, Inc. scores 23/100 on it among other operating companies.

Leverage
62

Pediatrix Medical Group, Inc.'s net debt of $195.3M, being $570.5M of long-term debt less $375.2M of cash, came to 0.85 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Pediatrix Medical Group, Inc. scores 62/100 among other operating companies measured the same way.

Liquidity
49

Pediatrix Medical Group, Inc. held $1.66 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.66. Liquidity ranks operating companies on that ratio, and Pediatrix Medical Group, Inc. scores 49/100 among other operating companies.

Cash Flow
n/a

Not available for Pediatrix Medical Group, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

Returns
41

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Pediatrix Medical Group, Inc. scores 41/100 on it among other operating companies.

Altman Z-Score Grey Zone
2.32

Pediatrix Medical Group, Inc. scores 2.32, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $2.4B against total liabilities of $1.4B. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
7/8

Pediatrix Medical Group, Inc. passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality Cash-Backed
1.64x

For every $1 of reported earnings, Pediatrix Medical Group, Inc. generates $1.64 in operating cash flow ($271.1M OCF vs $165.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
5.81x

Pediatrix Medical Group, Inc. earns $5.81 in operating income for every $1 of interest expense ($208.8M vs $36.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$501.4M
YoY+1.7%
QoQ+2.8%
5Y CAGR+0.3%

Pediatrix Medical Group, Inc. generated $501.4M in revenue in Q3 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 2.8%.

EBITDA
$71.5M
YoY-2.9%
QoQ+14.0%
5Y CAGR+1.3%
10Y CAGR-8.9%

Pediatrix Medical Group, Inc.'s EBITDA was $71.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.9% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.

Net Income
$47.0M
YoY-34.5%
QoQ+17.9%
5Y CAGR+8.8%
10Y CAGR-6.9%

Pediatrix Medical Group, Inc. reported $47.0M in net income in Q3 2026. This represents a decrease of 34.5% from the same quarter a year earlier. Against the prior quarter it is up 17.9%.

EPS (Diluted)
$0.59
YoY-29.8%
QoQ+20.4%

Pediatrix Medical Group, Inc. earned $0.59 per diluted share (EPS) in Q3 2026. This represents a decrease of 29.8% from the same quarter a year earlier. Against the prior quarter it is up 20.4%.

Cash & Balance Sheet

Cash & Debt
$311.9M
YoY-8.3%
QoQ+8.0%
5Y CAGR-2.7%
10Y CAGR+19.4%

Pediatrix Medical Group, Inc. held $311.9M in cash against $397.8M in long-term debt as of Q3 2026.

Shares Outstanding
78M
YoY-9.0%
QoQ-3.9%

Pediatrix Medical Group, Inc. had 78M shares outstanding in Q3 2026. This represents a decrease of 9.0% from the same quarter a year earlier. Against the prior quarter it is down 3.9%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
13.0%
YoY-0.8pp
QoQ+1.3pp
5Y change+1.1pp

Pediatrix Medical Group, Inc.'s operating margin was 13.0% in Q3 2026, reflecting core business profitability. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.

Net Margin
9.4%
YoY-5.2pp
QoQ+1.2pp
5Y change+3.1pp

Pediatrix Medical Group, Inc.'s net profit margin was 9.4% in Q3 2026, showing the share of revenue converted to profit. This is down 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Return on Equity
5.5%
YoY-2.5pp
QoQ+1.0pp
5Y change+1.9pp
10Y change+1.9pp

Pediatrix Medical Group, Inc.'s quarterly ROE was 5.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.

Gross Margin

Not reported for Q3 2026.

Capital Allocation

Share Buybacks
$83.0M
YoY+298.0%
QoQ+94.3%
5Y CAGR+101.9%

Pediatrix Medical Group, Inc. spent $83.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 298.0% from the same quarter a year earlier. Against the prior quarter it is up 94.3%.

R&D Spending

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

MD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MD quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$501.4M+1.7%$487.8M+4.0%$476.2M+3.9%$493.8M-1.7%$492.9M-3.6%$468.8M-7.0%$458.4M-7.4%$502.4M+1.2%
SG&A Expenses$62.7M+3.1%$61.3M+10.0%$60.3M+2.8%$65.7M+3.3%$60.8M+4.6%$55.7M-1.5%$58.6M-2.6%$63.6M+19.8%
Operating Income$65.2M-4.2%$56.9M-4.9%$41.7M+29.8%$48.8M+24.2%$68.1M+101.2%$59.9Mn/m$32.1M+102.0%$39.3Mn/m
EBITDA$71.5M-2.9%$62.7M-3.8%$47.8M+27.6%$54.4M+17.9%$73.6M+83.6%$65.2Mn/m$37.4M+42.9%$46.2Mn/m
Interest Expense$8.1M-9.1%$8.2M-10.5%$8.3M-9.7%$8.7M-10.0%$8.9M-11.7%$9.1M-11.4%$9.2M-13.6%$9.7M-3.7%
Income Tax$18.0M+12.0%$14.2M-9.9%$9.3M+26.1%$11.9M+318.3%$16.1M+177.4%$15.7Mn/m$7.4M+94.1%$2.8Mn/m
Net Income$47.0M-34.5%$39.8M+1.5%$29.6M+42.6%$33.7M+10.5%$71.7M+268.8%$39.3Mn/m$20.7M+413.9%$30.5Mn/m
EPS (Basic)$0.61-28.2%$0.50+8.7%$0.37+48.0%$0.41+10.8%$0.85+269.6%$0.46n/m$0.25+400.0%$0.37
EPS (Diluted)$0.59-29.8%$0.49+6.5%$0.36+50.0%$0.40+8.1%$0.84+265.2%$0.46n/m$0.24+380.0%$0.37
Diluted Shares (Avg)80M-6.9%81M-4.8%83M-2.8%N/A86M+1.3%86M+2.6%85M+2.6%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

MD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MD quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$2.1B-2.7%$2.1B+1.3%$2.1B+3.9%$2.2B+4.4%$2.2B+5.9%$2.1B+5.3%$2.0B-8.1%$2.2B-3.0%
Current Assets$684.1M-4.6%$660.1M+7.7%$587.0M+19.4%$763.5M+19.4%$717.2M+35.8%$613.0M+42.8%$491.7M+15.3%$639.6M+32.3%
Cash & Equivalents$311.9M-8.3%$288.9M+28.5%$205.8M+107.9%$375.2M+63.2%$340.1M+227.5%$224.7M+1058.3%$99.0M+1137.5%$229.9M+213.9%
Short-Term Investments$113.9M-7.4%$115.3M-6.7%$123.2M+2.5%$124.5M+5.0%$123.0M+5.5%$123.6M+8.6%$120.2M+11.8%$118.6M+13.5%
Accounts Receivable$231.8M+0.3%$227.6M-4.8%$224.8M-7.3%$229.7M-11.7%$231.1M-19.4%$239.0M-12.8%$242.5M-14.5%$260.0M-4.5%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$1.3B+1.0%$1.3B+2.1%$1.3B+2.1%$1.3B+1.5%$1.3B+1.3%$1.2B+0.3%$1.2B-10.8%$1.2B-10.2%
Total Liabilities$1.3B-1.4%$1.2B-1.5%$1.2B-1.0%$1.4B-0.5%$1.3B-2.7%$1.3B-1.6%$1.2B-8.2%$1.4B+1.2%
Current Liabilities$535.7M+36.5%$501.6M+47.1%$442.6M+63.3%$458.9M+5.7%$392.5M+5.2%$341.0M+10.0%$271.1M+9.6%$434.1M+11.6%
Non-Current Liabilities$754.1M-17.7%$747.8M-19.4%$749.1M-19.7%$921.9M-3.3%$916.2M-5.7%$927.3M-5.3%$933.2M-12.3%$953.7M-2.9%
Long-Term Debt$397.8M-31.1%$398.1M-31.8%$398.3M-32.5%$570.5M-4.5%$577.2M$583.9M$590.5M$597.1M-3.4%
Total Equity$849.6M-4.6%$881.0M+5.7%$878.6M+11.3%$865.9M+13.2%$890.7M+21.6%$833.8M+18.0%$789.2M-7.8%$764.9M-9.9%
Retained Earnings$0n/m-$13.7Mn/m-$53.6Mn/m-$83.2Mn/m-$116.8Mn/m-$188.5Mn/m-$227.8Mn/m-$248.5Mn/m

Not reported in any period shown, so not listed: Inventory.

MD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MD quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$117.3M-14.6%$125.3M-8.6%-$129.8Mn/m$114.1M-14.2%$137.3M+49.5%$137.2M+28.3%-$117.5Mn/m$133.0M+92.1%
Depreciation & Amortization$6.2M+12.5%$5.8M+8.8%$6.1M+14.8%$5.6M-18.1%$5.6M-11.2%$5.3M-39.6%$5.3M-48.3%$6.9M-24.2%
Stock-Based CompensationN/AN/A$4.7M+28.0%N/A$3.4M+30.8%$2.0M0.0%$3.6M+18.7%N/A
Investing Cash Flow-$4.6M-170.3%$6.0Mn/m-$12.0Mn/m-$10.3Mn/m$6.6Mn/m-$7.2Mn/m-$7.5Mn/m-$1.9Mn/m
Financing Cash Flow-$89.6Mn/m-$48.2Mn/m-$27.6Mn/m-$68.6Mn/m-$28.6Mn/m-$4.3Mn/m-$6.0M-107.9%-$5.0Mn/m
Share Buybacks$83.0M+298.0%$42.7M+20351.7%$21.5M+1267.2%$64.0M+9859.3%$20.9M+12780.9%$209K+1800.0%$1.6M+76.9%$643Kn/m

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

MD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MD quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin13.0%-0.8pp11.7%-1.1pp8.8%+1.7pp9.9%+2.1pp13.8%+7.2pp12.8%+44.0pp7.0%+3.8pp7.8%+30.3pp
Net Margin9.4%-5.2pp8.2%-0.2pp6.2%+1.7pp6.8%+0.8pp14.5%+10.7pp8.4%+38.7pp4.5%+3.7pp6.1%+31.1pp
Return on Equity5.5%-2.5pp4.5%-0.2pp3.4%+0.7pp3.9%-0.1pp8.1%+5.4pp4.7%+26.4pp2.6%+2.2pp4.0%+18.6pp
Return on Assets2.2%-1.1pp1.9%0.0pp1.4%+0.4pp1.5%+0.1pp3.3%+2.3pp1.9%+9.5pp1.0%+0.8pp1.4%+7.0pp
Current Ratio1.28-0.6x1.32-0.5x1.33-0.5x1.66+0.2x1.83+0.4x1.80+0.4x1.81+0.1x1.47+0.2x
Debt-to-Equity0.47-0.2x0.45-0.2x0.45-0.3x0.66-0.1x0.650.700.750.78+0.1x
Liabilities-to-Equity1.520.0x1.42-0.1x1.36-0.2x1.59-0.2x1.47-0.4x1.52-0.3x1.530.0x1.81+0.2x
Asset Turnover0.230.0x0.230.0x0.230.0x0.220.0x0.220.0x0.220.0x0.230.0x0.230.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Pediatrix Medical Group, Inc. MD FY2025 $1.9B $165.4M 8.6% $2.4B 44/100
Aveanna Healthcare Holdings Inc. AVAH FY2026 $2.4B $225.0M 9.3% $2.4B 44/100
Ardent Health, Inc. ARDT FY2025 $6.3B $135.8M 2.1% $2.0B 54/100
Addus HomeCare Corp. ADUS FY2025 $1.4B $95.9M 6.7% $2.3B 68/100
Brookdale Senior Living, Inc. BKD FY2025 $3.2B -$262.7M -8.2% $2.1B 24/100
Surgery Partners, Inc. SGRY FY2025 $3.3B -$77.9M -2.4% $3.5B 54/100

Frequently Asked Questions

Pediatrix Medical Group, Inc. (MD) reported $1.9B in total revenue for fiscal year 2025. This represents a -4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Pediatrix Medical Group, Inc. (MD) revenue declined by 4.9% year-over-year, from $2.0B to $1.9B in fiscal year 2025.

Yes, Pediatrix Medical Group, Inc. (MD) reported a net income of $150.1M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $165.4M, with a net profit margin of 8.6%.

Pediatrix Medical Group, Inc. (MD) reported diluted earnings per share of $1.94 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pediatrix Medical Group, Inc. (MD) had EBITDA of $230.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Pediatrix Medical Group, Inc. (MD) had $375.2M in cash and equivalents against $570.5M in long-term debt.

Pediatrix Medical Group, Inc. (MD) had an operating margin of 10.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Pediatrix Medical Group, Inc. (MD) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Pediatrix Medical Group, Inc. (MD) has a return on equity of 19.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Pediatrix Medical Group, Inc. (MD) generated $271.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Pediatrix Medical Group, Inc. (MD) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.

Yes, Pediatrix Medical Group, Inc. (MD) spent $86.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Pediatrix Medical Group, Inc. (MD) had 83M shares outstanding as of fiscal year 2025.

Pediatrix Medical Group, Inc. (MD) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.

Pediatrix Medical Group, Inc. (MD) had a debt-to-equity ratio of 0.66 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Pediatrix Medical Group, Inc. (MD) had a liabilities-to-equity ratio of 1.59 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Pediatrix Medical Group, Inc. (MD) had a return on assets of 7.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Pediatrix Medical Group, Inc. (MD) trades at 16.1x earnings, its market capitalization divided by $150.1M net income, trailing 12 months to September 30, 2026. The market capitalization is $2.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Pediatrix Medical Group, Inc. (MD) trades at 1.2x sales, its market capitalization divided by $2.0B revenue, trailing 12 months to September 30, 2026. The market capitalization is $2.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Pediatrix Medical Group, Inc. (MD) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Pediatrix Medical Group, Inc. (MD) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Pediatrix Medical Group, Inc. (MD) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Pediatrix Medical Group, Inc. (MD) has an interest coverage ratio of 5.81x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Pediatrix Medical Group, Inc. (MD) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Pediatrix Medical Group, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top